Immune therapy for age-related diseases

Trends in Immunology

Volumn 30, Issue 7, 2009, Pages 344-350

  Weksler, Marc E ^a   Pawelec, Graham ^b   Franceschi, Claudio ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; APOLIPOPROTEIN E; IMMUNOGLOBULIN; INFLIXIMAB; PHOSPHORYLCHOLINE; PLACEBO; RAPAMYCIN; VARICELLA ZOSTER VACCINE;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CHICKENPOX; CLINICAL TRIAL; DISEASE COURSE; HERPES ZOSTER; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; PROPHYLAXIS; REVIEW; SENESCENCE; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS ACTIVATION; VIRUS STRAIN;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ARTERIOSCLEROSIS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOTHERAPY, ACTIVE; LIPOPROTEINS, LDL; MICE; VIRAL VACCINES;

EID: 67649402294     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2009.03.011     Document Type: Review

References (48)

1. Statistics Division of the United Nations. (2006) Population and Vital Statistics Report for 2006. Statistics Division of the United Nations Department of Economic and Social Affairs
2. Oxman M.N. Clinical manifestations of herpes zoster. In: Arvin A., and Gershon A.A. (Eds). Varicella-Zoster Virus: Virology and Clinical Management (2000), Cambridge University Press 246-275
3. Straus S.E., et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N. Engl. J. Med. 311 (1984) 1362-1364
4. Breuer J. Studies on shingles, is the virus ordinary chickenpox virus?. Rev. Med. Virol. 12 (2002) 5-11
5. Hope-Simpson R.E. The Nature of Herpes Zoster: A Long-term Study and a new hypothesis. Proc. R. Soc. Med. 58 (1965) 9-20
6. Levin M. Immunization against herpes zoster. In: Arvin A., and Gershon A.A. (Eds). Varicella-Zoster Virus: Virology and Clinical Management (2000), Cambridge University Press 500-519
7. Burke B.L., et al. Immune responses to varicella-zoster in the aged. Arch. Intern. Med. 142 (1982) 291-293
8. Oxman M.N., et al., Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352 (2005) 2271-2284
9. Oxman M.N., Levin M.J., and Shingles Prevention Study Group. Vaccination against Herpes Zoster and Postherpetic Neuralgia. J. Infect. Dis. 197 Suppl 2 (2008) S228-S236
10. Levin M.J., et al. VZV-specific immune responses in elderly recipients of a Herpes Zoster Vaccine. J. Infect. Dis. 197 (2008) 825-835
11. Harpaz R., et al. Advisory Committee on immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 57 RR-5 (2008) 1-30
12. Glenner G.G. The pathobiology of Alzheimer's disease. Annu. Rev. Med. 40 (1989) 45-51
13. Masters C.L., et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4245-4249
14. Hutton M., and Hardy J. The presenilins and Alzheimer's disease. Hum. Mol. Genet. 6 (1997) 1639-1646
15. Games D., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
16. Morrissette D.A., et al. Relevance of transgenic mouse models to human Alzheimer disease. J. Biol. Chem. 284 (2009) 6033-6037
17. Solomon B., et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4109-4112
18. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
19. Morgan D., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
20. Bard F., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
21. Wisniewski T., and Konietzko U. Amyloid-beta immunization for Alzheimer's disease. Lancet Neurol. 7 (2008) 805-811
22. Gilman S., et al. AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
23. Weksler M.E., et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37 (2002) 943-948
24. Dodel R., et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 52 (2002) 253-256
25. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2008 Feb 20 [Epub ahead of print]
26. Dodel R.C., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1472-1474
27. th Meeting of the European Neurological Society June 9, 2008
28. A phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV10%) for the treatment of mild to moderate Alzheimer's Disease NCT00818662 http://clinicaltrials.gov
29. O'Nuallain B, Acero L, Williams AD, McWilliams Koeppen HP, Weber A, Schwarz HP, Wall JS, Weiss DT, Solomon A. Human Plasma Contains Cross-Reactive Abeta Conformer-Specific IgG Antibodies. Biochemistry. 2008 Oct 29 [Epub ahead of print]
30. Kieseier B.C., et al. Intravenous immunoglobulins in the treatment of immune neuropathies. Curr. Opin. Neurol. 21 (2008) 555-562
31. Mishto M., et al. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging 27 (2006) 54-66
32. Hansson G.K. Inflammation, Atherosclerosis, and Coronary Artery Disease. N. Engl. J. Med. 352 (2005) 1685-1695
33. Kearney J.F. Immune recognition of OxLDL in atherosclerosis. J. Clin. Invest. 105 (2000) 1683-1685
34. Ridker P.M., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359 (2008) 2195-2207
35. Grabar P. Hypothesis. Auto-antibodies and immunological theories: an analytical review. Clin. Immunol. Immunopathol 4 (1975) 453-466
36. Meroni P.L., et al. Anti-beta 2 glycoprotein I antibodies in centenarians. Exp. Gerontol. 39 (2004) 1459-1465
37. Robinette C.D., and Fraumeni Jr. J.F. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet 2 (1977) 127-129
38. Amlot P.L., and Hayes A.E. Impaired human antibody response to the thymus-independent antigen, DNP-Ficoll, after splenectomy. Implications for post-splenectomy infections. Lancet 1 (1985) 1008-1011
39. Caligiuri G., et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109 (2002) 745-753
40. Shaw P.X., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105 (2000) 1731-1740
41. Binder C.J., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9 (2003) 736-743
42. Damoiseaux J., et al. Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an anti-atherogenic effect. Atherosclerosis 190 (2007) 10-11
43. Caligiuri G., et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50 (2007) 540-546
44. Su J., et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188 (2006) 160-166
45. Chan C., et al. DECODE Investigators. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study, Catheter. Cardiovasc. Interv. 72 (2008) 591-600
46. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured?. Nutr. Rev. 65 (2007) S173-S176
47. Larbi A., et al. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 23 (2008) 64-74
48. Franceschi C., et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 129 (2007) 92-105